Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.25.1 (
proteasome
)
28,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recent research advances highlighted an intestinal goblet cell-produced lectin, intelectin-1 (also known as omentin-1), as a tumor suppressor. One study indicated that downregulation of intelectin-1 may be related to the unfavorable prognosis among patients with colorectal carcinoma at an advanced stage. The present study was aimed at analyzing the expression of a hitherto uncharacterized transmembrane protein
TMEM207
in colorectal carcinoma, and we found that the
TMEM207
function is linked to intelectin-1 processing. With specific antibodies,
TMEM207
immunoreactivity was detected in 38 of 216 colorectal cancer tissue samples.
TMEM207
immunoreactivity correlated inversely with lymph node metastatic status (p < 0.01).
TMEM207
expression significantly correlated with the mucinous phenotype of colorectal carcinoma. A coimmunoprecipitation assay revealed an interaction between intelectin-1 and
TMEM207
in colorectal cancer cells. A proximal ligation assay indicated that intelectin-1 and
TMEM207
were colocalized to the cytoplasm of the colorectal cancer cells. A small-interfering-RNA-mediated knockdown of
TMEM207
increased polyubiquitination and
proteasome
degradation of intelectin-1 in cultured colorectal cancer cells and decreased intelectin-1 secretion. These findings indicate that a loss of
TMEM207
expression leads to insufficient intelectin-1 production thus promoting colorectal carcinogenesis.
...
PMID:Expression of TMEM207 in Colorectal Cancer: Relation between TMEM207 and Intelectin-1. 2681 45
